Healthcare / Health Information ServicesHKSE
$5.03
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $75.6M · quality 75.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
50/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.0B
P/E
21.0x
↑EV/EBITDA
15.9x
↑ROE
12.4%
↑Gross Margin
59.4%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+5.5%
FCF CAGR
+32.7%
FCF margin
15.8%
FCF / Net income
0.71x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $419.1M · net income $93.4M · FCF $66.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $419.1M | $419.1M | $403.7M | $396.2M | $356.7M |
| Net Income | $93.4M | $93.4M | $110.6M | $102.0M | $55.8M |
| EBITDA | $114.5M | $114.5M | $128.8M | $119.9M | $63.6M |
| EPS | — | — | 0.27 | 0.24 | 0.14 |
| Gross Margin | 59.4% | 59.4% | 57.8% | 56.4% | 44.6% |
| Operating Margin | 24.7% | 24.7% | 25.5% | 27.0% | 9.4% |
| Net Margin | 22.3% | 22.3% | 27.4% | 25.8% | 15.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.02 | 0.02 | 0.01 |
| Current Ratio | 7.21 | 7.21 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $66.4M | $66.4M | $88.4M | $75.6M | $28.4M |
| Returns | |||||
| ROE | 12.4% | 12.4% | 15.6% | 14.5% | 8.0% |
| Valuation | |||||
| P/E | 20.96 | 20.96 | 19.99 | 24.81 | 34.61 |
| EV/EBITDA | 15.93 | 15.93 | 16.76 | 20.19 | 24.02 |
| P/B | 2.72 | 2.72 | 3.11 | 3.60 | 2.78 |
| Growth & Yield | |||||
| Revenue Growth | 3.8% | 3.8% | 1.9% | 11.1% | — |
| EPS Growth | — | — | 12.7% | 76.3% | — |
| Dividend Yield | 1.4% | 1.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+63.7%
Start / end P/E
n/dx → n/dx
EPS bridge
0.27 → n/d
Residual
+62.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.